Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences
Exploration of Targeted Anti-tumor Therapy, 2022 Antibody-drug conjugates (ADCs) are a recent, revolutionary approach for malignancies treatment, designed to provide superior efficacy and specific targeting of tumor cells, compared to systemic cytotoxic chemotherapy.
Marilia Barreca +5 more
doaj +1 more source
Progresses in research and development of antibody-drug conjugate
生物医学转化, 2021 Through referring to the literature and related databases, the research process of antibodyconjugated drugs was reviewed, and the key elements of ADC were summarized.
Wu Gang +6 more
doaj +1 more source
Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload
Pharmaceutics, 2023 Antibody–drug conjugates (ADCs) are at the forefront of the drug development revolution occurring in oncology. Formed from three main components—an antibody, a linker molecule, and a cytotoxic agent (“payload”), ADCs have the unique ability to deliver ...
A. Kondrashov +5 more
semanticscholar +1 more source
Efficient Prodrug Activator Gene Therapy by Retroviral Replicating Vectors Prolongs Survival in an Immune-Competent Intracerebral Glioma Model. [PDF]
, 2020 Prodrug activator gene therapy mediated by murine leukemia virus (MLV)-based retroviral replicating vectors (RRV) was previously shown to be highly effective in killing glioma cells both in culture and in vivo.
Chang, Deching +13 more
core +2 more sources
Adriamycin loading and release characteristics of albumin-heparin conjugate microspheres [PDF]
, 1994 Biodegradable ion-exchange microspheres, prepared from a prefabricated conjugate of albumin and heparin were investigated as carriers for adriamycin. The ion-exchange microspheres could be loaded with adriamycin giving payloads up to 33% w/w, depending ...
Bae, Y.H. +6 more
core +2 more sources
A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy. [PDF]
, 2015 Although recent methods for the engineering of antibody-drug conjugates (ADCs) have gone some way to addressing the challenging issues of ADC construction, significant hurdles still remain.
Caddick, S +5 more
core +1 more source
Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors
Molecules, 2023 Antibody–drug conjugates (ADCs) are a new class of targeted anti-cancer therapies that combine a monoclonal tumor-surface-receptor-targeting antibody with a highly cytotoxic molecule payload bonded through specifically designed cleavable or non-cleavable
Blair McNamara +4 more
doaj +1 more source
Antibody Conjugation and Formulation [PDF]
, 2019 In an era where ultra-high antibody concentrations, high viscosities, low volumes, auto-injectors, and long storage requirements are already complex problems with the current unconjugated monoclonal antibodies on the market the formulation demands for ...
Alves, Nathan J.
core +1 more source
Antibody–Drug Conjugates for Cancer Therapy
Molecules, 2020 Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the delivery of a potent cytotoxic payload.
Umbreen Hafeez +3 more
doaj +1 more source
Pharmaceuticals, 2021 Combining the selective targeting of tumor cells through antigen-directed recognition and potent cell-killing by cytotoxic payloads, antibody-drug conjugates (ADCs) have emerged in recent years as an efficient therapeutic approach for the treatment of ...
Vesela Kostova +3 more
doaj +1 more source